U.S. markets close in 8 minutes

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
5.03+1.54 (+44.21%)
A partir del 03:52PM EDT. Mercado abierto.

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
Australia
61 3 9639 6036
https://www.mesoblast.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo83

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director738.74kN/D1957
Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director625.46kN/D1951
Mr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerN/DN/DN/D
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)General Counsel & Corporate ExecutiveN/DN/D1968
Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersN/DN/DN/D
Mr. Michael Schuster BSc, M.B.A., MSHead of Pharma PartneringN/DN/D1977
Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality ManagementN/DN/DN/D
Mr. Justin Horst B.S.Head of ManufacturingN/DN/DN/D
Ms. Niva Sivakumar B.Com., L.L.B.Joint Company SecretaryN/DN/DN/D
Mr. Paul Hughes BPHARMJoint Company SecretaryN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Gestión corporativa

La calificación ISS Governance QuickScore de Mesoblast Limited a partir del 1 de marzo de 2024 es 6. Las puntuaciones principales son Auditoría: 9; Junta: 4; Derechos del accionista: 10; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.